Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.00 is 100% below its 5-year average of 0.02, near the low end of its 5-year range (-2.69–7.42).
As of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00.
DEBT TO EQUITY RATIO
0.00
DEBT TO EQUITY RATIO AVG TTM
0.00
DEBT TO EQUITY RATIO AVG 3Y
-0.12
DEBT TO EQUITY RATIO AVG 5Y
0.02
DEBT TO EQUITY RATIO AVG 10Y
0.26
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
+100.00%
CURRENT VS 5Y AVG
-100.00%
CURRENT VS 10Y AVG
-100.00%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.11
median of 774 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
Eloxx Pharmaceuticals, Inc.
Market Cap
$50.31M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
-0.12
5Y Avg
0.02
Market Cap
$50.58M
Debt to Equity Ratio
0.25
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
Market Cap
$49.58M
Debt to Equity Ratio
0.20
TTM Avg
0.18
3Y Avg
0.24
5Y Avg
0.23
Market Cap
$49.44M
Debt to Equity Ratio
0.01
TTM Avg
0.02
3Y Avg
0.04
5Y Avg
0.04
Market Cap
$51.33M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.15
5Y Avg
0.12
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Eloxx Pharmaceuticals, Inc. (ELOX) | $50.31M | 0.00 | 0.00 | -0.12 | 0.02 |
| Envoy Medical, Inc. (COCH)vs › | $50.58M | 0.25 | 0.00 | 0.00 | 0.00 |
| Clene Inc. (CLNN)vs › | $50.68M | N/A | 6.12 | 6.71 | 4.67 |
| Precision Optics Corporation, Inc. (POCI)vs › | $49.58M | 0.20 | 0.18 | 0.24 | 0.23 |
| INmune Bio, Inc. (INMB)vs › | $49.58M | 0.07 | 0.03 | 0.14 | 0.13 |
| eXoZymes, Inc. (EXOZ)vs › | $51.23M | 0.30 | 0.25 | 0.31 | 0.39 |
| biote Corp. (BTMD)vs › | $51.83M | N/A | 9.05 | 9.05 | 9.05 |
| Microbot Medical Inc. (MBOT)vs › | $49.44M | 0.01 | 0.02 | 0.04 | 0.04 |
| Tenax Therapeutics, Inc. (TENX)vs › | $51.33M | 0.00 | 0.00 | 0.15 | 0.12 |
| TELA Bio, Inc. (TELA)vs › | $49.21M | N/A | 5.17 | 3.87 | 2.95 |
Debt/Equity
0.00
Current Ratio
3.74
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.00 |
| 2026-03-31 | 0.00 |
| 2025-03-31 | 0.00 |
| 2023-09-30 | -0.29 |
| 2023-06-30 | -0.33 |
| 2023-03-31 | -0.38 |
| 2022-12-31 | -1.26 |
| 2022-09-30 | -2.69 |
| 2022-06-30 | 7.42 |
| 2022-03-31 | 1.15 |
| 2021-12-31 | 0.60 |
| 2021-09-30 | 0.41 |
| 2021-06-30 | 0.28 |
| 2021-03-31 | 3.91 |
| 2020-12-31 | 1.18 |
| 2020-09-30 | 0.88 |
| 2020-06-30 | 0.72 |
| 2020-03-31 | 0.57 |
| 2019-12-31 | 0.44 |
| 2019-09-30 | 0.34 |
| 2019-06-30 | 0.28 |
| 2019-03-31 | 0.45 |
| 2018-12-31 | 0.00 |
| 2018-09-30 | 0.00 |
| 2018-06-30 | 0.00 |
| 2018-03-31 | 0.00 |
| 2017-06-30 | 0.47 |
| 2017-03-31 | 0.10 |
| 2016-12-31 | 0.11 |
| 2016-09-30 | 0.00 |
| 2016-06-30 | 0.00 |
| 2016-03-31 | 0.00 |
| 2015-12-31 | 0.00 |
| 2015-09-30 | 0.00 |
